MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Arbutus Biopharma Corp

Closed

3.12 -1.58

Overview

Share price change

24h

Current

Min

3.11

Max

3.24

Key metrics

By Trading Economics

Income

-12M

-25M

Sales

190K

1.8M

Profit margin

-1,390.363

Employees

44

EBITDA

-12M

-24M

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-21M

621M

Previous open

4.7

Previous close

3.12

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Arbutus Biopharma Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 lip 2025, 23:41 UTC

Market Talk

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 lip 2025, 23:40 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 lip 2025, 23:05 UTC

Market Talk

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 lip 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 lip 2025, 21:36 UTC

Market Talk

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 lip 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 lip 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

15 lip 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 lip 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

15 lip 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 lip 2025, 20:07 UTC

Earnings

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 lip 2025, 20:06 UTC

Market Talk

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 lip 2025, 19:54 UTC

Market Talk

Global Equities Roundup: Market Talk

15 lip 2025, 19:54 UTC

Market Talk

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 lip 2025, 19:38 UTC

Market Talk

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 lip 2025, 19:09 UTC

Market Talk

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 lip 2025, 19:07 UTC

Market Talk

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 lip 2025, 19:03 UTC

Market Talk

Gold Slips as Big Buyers Pull Back -- Market Talk

15 lip 2025, 18:32 UTC

Acquisitions, Mergers, Takeovers

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 lip 2025, 18:31 UTC

Acquisitions, Mergers, Takeovers

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 lip 2025, 18:13 UTC

Market Talk

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 lip 2025, 17:40 UTC

Market Talk

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 lip 2025, 17:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 lip 2025, 17:25 UTC

Acquisitions, Mergers, Takeovers

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 lip 2025, 17:24 UTC

Market Talk

Dollar Gains Strength After Inflation Data -- Market Talk

15 lip 2025, 16:49 UTC

Market Talk

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 lip 2025, 16:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

15 lip 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 lip 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

15 lip 2025, 15:42 UTC

Market Talk

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Peer Comparison

Price change

Arbutus Biopharma Corp Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.255 / 3.365Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.